Drug development or mental health clinics? We explore the benefits of both business strategies for investors in psychedelic stocks.
Drug development or mental health clinics? We explore the benefits of both business strategies for investors in psychedelic stocks.
MINDCURE's new COO, Tarik Lebbadi, recently led an international division of Johnson & Johnson.
The psychedelic drug industry continues to advance by leaps-and-bounds. But psychedelic drug stocks are well off recent highs. The sale is on!
This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform
If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now